BillsHH.R. 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Stage
In committee
Latest action
Referred to the House Committee on Energy and Commerce.
March 5, 2025
Summary
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed
Committees
- PrimaryEnergy and Commerce Committee
Action history
- March 5, 2025Introduced in House
- March 5, 2025Introduced in House
- March 5, 2025Referred to the House Committee on Energy and Commerce.
Cosponsors (1)
Text versions
- Introduced in HouseMarch 5, 2025